GLP-1 Tirzepatide & B6 60mg (20mg/mL)

Route: Subcutaneous injection once weekly. The 20 mg/mL concentration in a 3 mL vial allows three 20 mg doses (1 mL each) or six 10 mg doses (0.5 mL each), per prescriber direction. Rotate injection sites among abdomen, thigh, and upper arm. Use sterile technique with a new needle for every vial access.

Dosing is entirely prescriber-determined. This 60 mg vial at 20 mg/mL is suited for patients established at higher maintenance doses:

• Prescriber specifies draw volume per injection (e.g., 0.5 mL for 10 mg or 1 mL for 20 mg).
• Dose and titration schedule must not be altered by the patient without prescriber guidance.
• This multi-dose vial should be tracked for beyond-use date compliance.

• Tirzepatide: Activates both GIP receptors (enhancing insulin release and adipose metabolism) and GLP-1 receptors (augmenting glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and activating hypothalamic satiety circuits) — the combination produces complementary glycemic and weight-reducing effects.
• Pyridoxine (B6): Cofactor for synthesis of serotonin, dopamine, and GABA; may attenuate nausea mediated through brainstem GLP-1 receptor activation, supporting continued adherence at higher tirzepatide doses.

This 60 mg/3 mL multi-dose vial is designed for patients requiring a larger supply of high-dose tirzepatide. Prescriber-directed for management of type 2 diabetes or obesity-related comorbidities in patient-specific clinical contexts. Regular laboratory and clinical monitoring is essential at higher dose levels.

Monitoring: HbA1c, fasting glucose, renal function, pancreatitis vigilance, thyroid history, injection site inspection, and adherence assessment at each follow-up.

Contraindications:

• Personal or family history of medullary thyroid carcinoma or MEN2.
• Known hypersensitivity to tirzepatide or formulation components.

Warnings & Precautions:

• Thyroid C-cell tumor risk; pancreatitis; hypoglycemia with insulin or sulfonylureas; acute kidney injury; GI motility disorders; careful dose calculation required due to high concentration.
• Multi-dose vial: strict aseptic technique required to avoid contamination.

Drug Interactions:

• Delayed gastric emptying may affect oral drug absorption kinetics; additive hypoglycemia with insulin and secretagogues.

Common Side Effects: Nausea, vomiting, diarrhea, constipation, decreased appetite, abdominal pain, injection site reactions.

Store refrigerated at 2°C–8°C. Do not freeze. Protect from light. Use each draw with a new sterile needle; do not reuse needles in the multi-dose vial. Use within the beyond-use date assigned by Genesis Compounding. Discard any remaining solution after the beyond-use date.

How many weekly doses are in this vial?

The 60 mg vial at 20 mg/mL contains 3 mL. At 20 mg per dose (1 mL), it contains 3 doses. At 10 mg per dose (0.5 mL), it contains 6 doses. Your prescriber determines the exact dosing volume.

Why use a 20 mg/mL concentration?

Higher concentration reduces the injection volume needed for larger doses, which can improve comfort. This is particularly relevant for patients at 15–20 mg weekly maintenance dosing levels.

What are signs of pancreatitis I should watch for?

Severe, persistent abdominal pain — especially radiating to the back — accompanied by nausea or vomiting is a warning sign. Discontinue the medication and seek emergency evaluation immediately if these symptoms develop.

Is this an FDA-approved medication?

No. This is a patient-specific, prescriber-directed 503A compounded preparation from Genesis Compounding, not an FDA-approved compounded drug.

Can I store this at room temperature?

Refrigeration at 2°C–8°C is required. Brief exposure to room temperature (e.g., before injection) is acceptable, but do not store at room temperature for extended periods. Do not freeze. Follow the beyond-use date on the label.